NASDAQ:TVRD Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $1.01 -0.09 (-8.18%) Closing price 04:00 PM EasternExtended Trading$1.05 +0.04 (+3.96%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Tvardi Therapeutics Stock (NASDAQ:TVRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tvardi Therapeutics alerts:Sign Up Key Stats Today's Range$1.01▼$1.0850-Day Range$0.79▼$1.8752-Week Range$0.77▼$5.69Volume71,181 shsAverage Volume372,146 shsMarket Capitalization$13.49 millionP/E RatioN/ADividend YieldN/APrice Target$9.40Consensus RatingModerate Buy Company Overview Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis.Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform.Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products. The company was founded to develop therapies targeting STAT3.AI Generated. May Contain Errors. Read More Tvardi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreTVRD MarketRank™: 3.803872165495 of 5 starsTvardi Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 114th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingTvardi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTvardi Therapeutics has a consensus price target of $9.40, representing about 830.7% upside from its current price of $1.01.Amount of Analyst CoverageTvardi Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Tvardi Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tvardi Therapeutics are expected to decrease in the coming year, from ($2.23) to ($2.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tvardi Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tvardi Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTvardi Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.43% of the float of Tvardi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTvardi Therapeutics has a short interest ratio ("days to cover") of 2.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tvardi Therapeutics has recently decreased by 20.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTvardi Therapeutics does not currently pay a dividend.Dividend GrowthTvardi Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.26 News SentimentTvardi Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Tvardi Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.40% of the stock of Tvardi Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tvardi Therapeutics' insider trading history. Receive TVRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVRD Stock News HeadlinesTvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business UpdateNovember 13, 2026 | globenewswire.comChardan Initiates Tvardi Therapeutics at Buy With $8 Price TargetOctober 20, 2026 | marketscreener.comMThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 17 at 1:00 AM | Porter & Company (Ad)Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare ConferenceOctober 14, 2026 | markets.businessinsider.comTvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare ConferenceOctober 14, 2026 | globenewswire.comTvardi pubblica dati preclinici su inibitore STAT3 per la coliteSeptember 25, 2026 | it.investing.comNew Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)September 25, 2026 | finance.yahoo.comTvardi Therapeutics, Inc. Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In Ulcerative ColitisSeptember 25, 2026 | marketscreener.comMSee More Headlines TVRD Stock Analysis - Frequently Asked Questions How have TVRD shares performed this year? Tvardi Therapeutics' stock was trading at $4.30 at the beginning of the year. Since then, TVRD shares have decreased by 76.5% and is now trading at $1.01. How were Tvardi Therapeutics' earnings last quarter? Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its earnings results on Friday, November, 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.03. When did Tvardi Therapeutics IPO? Tvardi Therapeutics (TVRD) raised $60 million in an initial public offering on Friday, January 31st 2014. The company issued 5,000,000 shares at $11.00-$13.00 per share. Who are Tvardi Therapeutics' major shareholders? Top institutional shareholders of Tvardi Therapeutics include State Street Corp (0.25%). How do I buy shares of Tvardi Therapeutics? Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/13/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, TVRD's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TVRD Previous SymbolNASDAQ:TVRD CIK1346830 Webwww.tvarditherapeutics.com Phone(713) 489-8654Fax203-567-1510Employees12Year Founded2004Price Target and Rating Average Price Target for Tvardi Therapeutics$9.40 High Price Target$13.00 Low Price Target$5.00 Potential Upside/Downside+830.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-145.40% Return on Assets-91.11% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.87 Sales & Book Value Annual Sales$7.14 million Price / Sales1.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.45Miscellaneous Outstanding Shares13,340,000Free Float12,352,000Market Cap$13.47 million OptionableOptionable Beta0.37 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TVRD) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.